NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to ...
In its upcoming report, TransMedics (TMDX) is predicted by Wall Street analysts to post quarterly earnings of $0.18 per share, reflecting an increase of 50% compared to the same period last year.
TransMedics is revolutionizing organ transplant therapy with its FDA-approved Organ Care System. See why I rate TMDX stock as ...
Van ECK Associates Corp grew its holdings in TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 102.3% in the fourth ...
NEW YORK, Feb. 22, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX ...
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
The complaint alleges that TransMedics made false and misleading statements, while failing to disclose crucial information. Specifically, the suit contends that TransMedics used kickbacks ...
WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMD ...
TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ...
In truth, it appears that TransMedics fueled its growth by engaging in an anti-competitive scheme, including providing kickbacks to medical providers. The company further boosted growth by engaging in ...